UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13G/A

Under the Securities Exchange Act of 1934 (Amendment No. 1)*

Aurinia Pharmaceuticals Inc.

(Name of Issuer)

Common Shares, no par value

(Title of Class of Securities)

05156V102

(CUSIP Number)

December 31, 2019

(Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 \Box Rule 13d-1(b)

 \boxtimes Rule 13d-1(c)

 \Box Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP N	No. 05156V102						
1	NAMES OF REPORTING PERSONS Vivo Capital VIII, LLC						
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) (a) ⊠ (b) □ 						
3	SEC USE ONLY						
4	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware						
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		5	SOLE VOTING POWER 1,065,530 ⁽¹⁾				
		6	SHARED VOTING POWER				
		7					
		8	SHARED DISPOSITIVE POWER 0				
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1.065.530 ⁽¹⁾						
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)						
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 1.0% ⁽²⁾						
12	TYPE OF REPORTING PERSON (See Instructions)						

(1) The common shares of Aurinia Pharmaceuticals Inc. (the "Issuer") are held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P, as of January 24, 2020. Vivo Capital VIII, LLC is the general partner of Vivo Capital Fund VIII, L.P and Vivo Capital Surplus Fund VIII, LP.

(2) Based on 105,400,173 common shares of the Issuer outstanding as of December 10, 2019, as disclosed in the Prospectus Supplement No. 4 to the Short Form Base Shelf Prospectus dated March 26, 2018, filed by the Issuer on December 10, 2019.

CUSIP N	CUSIP No. 05156V102						
1	NAMES OF REPORTING PERSONS Vivo Capital IX, LLC						
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) (a) ⊠ (b) □						
3	SEC USE ONLY						
4	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware						
NUMBER OF		5	SOLE VOTING POWER 623,432 ⁽¹⁾				
BEN OV	SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		SHARED VOTING POWER 0				
RE P			SOLE DISPOSITIVE POWER 623,432 ⁽¹⁾				
			SHARED DISPOSITIVE POWER 0				
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 623,432 ⁽¹⁾						
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)						
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 0.6% ⁽²⁾						
12	TYPE OF REPORTING PERSON (See Instructions) OO						

(1) The common shares of the Issuer are held of record by Vivo Capital Fund IX, L.P., as of January 24, 2020. Vivo Capital IX, LLC is the general partner of Vivo Capital Fund IX, L.P.

(2) Based on 105,400,173 common shares of the Issuer outstanding as of December 10, 2019, as disclosed in the Prospectus Supplement No. 4 to the Short Form Base Shelf Prospectus dated March 26, 2018, filed by the Issuer on December 10, 2019.

3

CUSIP N	lo. 05156V102						
1	NAMES OF REPORTING PERSONS Vivo Opportunity, LLC						
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) (a) ⊠ (b) □						
3	SEC USE ONLY						
4	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware						
NUMBER OF		5	SOLE VOTING POWER 2,940,496 ⁽¹⁾				
BEN	SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		SHARED VOTING POWER 0				
RE P			7 SOLE DISPOSITIVE POWER 2,940,496 ⁽¹⁾				
			SHARED DISPOSITIVE POWER 0				
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,940,496 ⁽¹⁾						
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)						
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 2.8% ⁽²⁾						
12	TYPE OF REPORTING PERSON (See Instructions) OO						

(1) The common shares of the Issuer are held of record by Vivo Opportunity Fund, L.P., as of January 24, 2020. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund, L.P.

(2) Based on 105,400,173 common shares of the Issuer outstanding as of December 10, 2019, as disclosed in the Prospectus Supplement No. 4 to the Short Form Base Shelf Prospectus dated March 26, 2018, filed by the Issuer on December 10, 2019.

Item 1. (a) Name of Issuer:

Aurinia Pharmaceuticals Inc.

(b) Address of Issuer's Principal Executive Offices:

#1203-4464 Markham Street Victoria, British Columbia V8Z7X8

Item 2. (a) Name of Person Filing:

This Schedule 13G amendment is filed jointly by Vivo Capital VIII, LLC, Vivo Capital IX, LLC and Vivo Opportunity, LLC.

(b) Address of Principal Business Office or, if None, Residence:

192 Lytton Avenue, Palo Alto, CA 94301

(c) Citizenship:

Vivo Capital VIII, LLC is a Delaware limited liability company.

Vivo Capital IX, LLC is a Delaware limited liability company.

Vivo Opportunity, LLC is a Delaware limited liability company.

(d) Title of Class of Securities:

Common shares

(e) CUSIP Number:

05156V102

Item 3. If This Statement is Filed Pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), Check Whether the Person Filing is a:

(a) \square Broker or dealer registered under Section 15 of the Act.

- (b) \square Bank as defined in Section 3(a)(6) of the Act.
- (c) \Box Insurance company as defined in Section 3(a)(19) of the Act.
- (d) 🛛 Investment company registered under Section 8 of the Investment Company Act of 1940.
- (e) \Box An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
- (f) \Box An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
- (g) \Box A parent holding company or control person in accordance with § 240.13d-1(b)(l)(ii)(G);
- (h) \Box A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;
- (i) 🛛 A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;
- (j) \Box A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);
- (k) \Box Group, in accordance with § 240.13d-1(b)(l)(ii)(K).

If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1(ii)(j), please specify the type of institution:

Not Applicable.

Item 4. Ownership.

(a) Amount beneficially owned:

(1) Vivo Capital VIII, LLC

The 1, 065,530 common shares are held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. as of January 24, 2020. Vivo Capital VIII, LLC is the general partner of Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. The voting members of Vivo Capital VIII, LLC are Frank Kung, Edgar Engleman, Albert Cha, Shan Fu and Chen Yu, none of whom has individual voting or investment power with respect to these shares and each of whom disclaims beneficial ownership of such shares.

(2) Vivo Capital IX, LLC

The 623,432 common shares are held of record by Vivo Capital Fund IX, L.P., as of January 24, 2020. Vivo Capital IX, LLC is the general partner of Vivo Capital Fund IX, L.P. The voting members of Vivo Capital IX, LLC are Frank Kung, Edgar Engleman, Albert Cha, Shan Fu and Chen Yu, none of whom has individual voting or investment power with respect to these shares and each of whom disclaims beneficial ownership of such shares.

(3) Vivo Opportunity, LLC

The 2,940,496 common shares are held of record by Vivo Opportunity Fund, L.P., as of January 24, 2020. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund, L.P. The voting members of Vivo Opportunity, LLC are Albert Cha, Gaurav Aggarwal, Shan Fu, Frank Kung and Michael Chang, none of whom has individual voting or investment power with respect to these shares and each of whom disclaims beneficial ownership of such shares.

(b) Percent of class:

Vivo Capital VIII, LLC: 1.0%

Vivo Capital IX, LLC: 0.6%

Vivo Opportunity, LLC: 2.8%

(c) Number of shares as to which such person has:

(i) Sole power to vote or to direct the vote:

Vivo Capital VIII, LLC: 1,065,530 shares

Vivo Capital IX, LLC: 623,432 shares

Vivo Opportunity, LLC: 2,940,496 shares

- (ii) Shared power to vote or to direct the vote: 0
- (iii) Sole power to dispose or to direct the disposition of:

Vivo Capital VIII, LLC: 1,065,530 shares

Vivo Capital IX, LLC: 623,432 shares

Vivo Opportunity, LLC: 2,940,496 shares

(iv) Shared power to dispose of or to direct the disposition of: 0

Item 5. Ownership of Five Percent or Less of a Class.

Not Applicable.

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Not Applicable.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not Applicable.

Item 8. Identification and Classification of Members of the Group.

Not applicable.

Item 9. Notice of Dissolution of Group.

Not applicable.

Item 10. Certifications.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Vivo Capital VIII, LLC

February 13, 2020

(Date)

/s/ Albert Cha (Signature)

Managing Member

(Title)

Vivo Capital IX, LLC

February 13, 2020

(Date)

/s/ Albert Cha (Signature)

Managing Member (Title)

Vivo Opportunity, LLC

February 13, 2020 (Date)

/s/ Albert Cha

(Signature)

Managing Member (Title)

(1